Chemistry and Pharmacology of Drugs of Abuse Annual Symposium

其他项目信息-项目概要/摘要 这一建议是对为期两天的“化学与环境”研讨会的延续， 药物滥用药理学”（CPDA）研讨会于2016年首次举行， 药物发现中心（CDD），东北大学，波士顿，马萨诸塞州。的主要目的 研讨会是作为一个最新的，重要的，与研究相关的进展跨学科的博览会 在与物质使用障碍（SUD）相关的临床研究中。物质使用障碍（SUD）和 成瘾是对全球公共卫生的普遍威胁，威胁的性质不断演变， 改变我们的目标是解决目前关于SUD疾病机制的知识差距， 这些治疗方法是我们在解决这些医疗挑战方面存在局限性的根源。 一个主要的主题是整合药物化学，结构生物学，药理学，行为 药理学和临床实践，以告知新药物的设计、合成、优化和（预）临床特征分析 药物的治疗潜力。SUD的生物学和病因学是复杂的。行为、环境和 （epi）遗传因素共同调节神经元回路，影响脆弱性，认知，社会行为， 帮助建立SUD表型。这些神经生物学过程的细节 并没有得到很好的理解。此外，更好的标准化的药物寻求和服用的动物范例是 需要更好地模拟临床SUD病理学，并可用于准确评估新的 SUD药物。尽管取得了重大进展，但令人沮丧的是， 药物治疗可以达到持久的禁欲。我们的一贯目标是把会议的重点完全放在 物质使用障碍，并汇集了来自这些领域的领先从业者。而且还有 对SUD高危人群的紧急威胁，如缺乏情感药物治疗的“设计药物”， 需要持续的警惕和努力来打击。我们的目标是在每一个主题中包括解决紧急问题的主题。 由NIDA社区领导人和领先的研究确定的年度计划。这样的聚会提供了丰富的 让年轻的科学家有机会接触这个领域。我们的目标是激励和鼓励下一代 研究人员致力于这项奋进。我们做了相当大的努力来欢迎科学家 我们的目标是扩大这些努力。 一个关于SUD响应紧急威胁的重点会议具有很高的价值， SUD研究社区和不同选区的支持，从基础研究人员到医疗保健 供应商和公共卫生官员。这包括生物技术领域的科学家（如Astraea Therapeutics）， 领先的生物医学研究中心（例如Scripps研究所），研究密集型临床中心（例如， 姆克林医院/哈佛医学院、西奈山伊坎医学院）和来自 波士顿市长办公室我们的目标是进一步提高我们研讨会的公众形象。

OTHER PROJECT INFORMATION – PROJECT SUMMARY/ABSTRACT This proposal is a renewal for the tremendously successful two-day symposium “Chemistry and Pharmacology of Drugs of Abuse” (CPDA) symposium that first took place in 2016 under the auspices of the Center for Drug Discovery (CDD), Northeastern University, Boston, Massachusetts. The primary aim of the symposium is to serve as an interdisciplinary exposition of the most recent, important, research-related advances in (pre)clinical research related to Substance Use Disorder (SUD). Substance Use Disorders (SUDs) and addiction are pervasive threats to global public health and the nature of the threat is ever evolving and changing. Our goal is to address gaps in current knowledge concerning SUD disease mechanisms and treatments that are at the root of our limitations in solving these medical challenges. A major theme is the integration of medicinal chemistry, structural biology, pharmacology, behavioral pharmacology and clinical practice to inform the design, synthesis, optimization, and (pre)clinical profiling of new agents for their therapeutic potential. SUD biology and etiology are complex. Behavioral, environmental, and (epi)genetic factors conspire to modulate neuronal circuits to affect vulnerability, cognition, social behavior, and emotional state in ways that help establish a SUD phenotype. The details of these neurobiological processes are not well understood. In addition, better standardized animal paradigms of drug-seeking and -taking are required that better model clinical SUD pathology and can be used to accurately assess the potential of novel SUD drugs. Despite significant advances, there is a frustratingly limited number of safe and affective pharmacotherapies available to attain durable abstinence. Our continuing aim is to focus the meeting entirely on Substance Use Disorder and bring together leading practitioners from each of these fields. Moreover, there are emergent threats to at-risk SUD populations such as “designer drugs” that lack affective pharmacotherapy and require ongoing vigilance and effort to combat. We aim to include topics that address emergent issues in each year’s program as identified by NIDA community leaders and leading research. Such a gathering offers a rich opportunity to expose young scientists to the field. We aim to inspire and encourage the next generation of researchers to devote themselves to this endeavor. We have made considerable efforts to welcome scientists from underserved and underrepresented populations and we aim to expand these efforts. A focused meeting on SUD responsive to emergent threats is of high value and has garnered much support by the SUD research community and diverse constituencies, from basic researchers to healthcare providers and public-health officials. This included scientists from biotechnology (e.g. Astraea Therapeutics), leading biomedical research centers (e.g. Scripps Research Institute), research-intensive clinical centers (e.g., McLean Hospital/Harvard Medical School, Icahn School of Medicine at Mount Sinai) and representatives from the City of Boston Mayor’s office. Our goal is to further raise the public profile of our symposium.